Feng Lu

Dr. Feng Lu

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
ZHzhang hang
zhang hang
NLNannan Li
Nannan Li
YZYukun Zhang
Yukun Zhang
YXYue Xu
Yue Xu
FLFeng Lu
Feng Lu
YBYang Baoxue
Yang Baoxue
Chemotherapy is an important factor leading to male infertility. It is crucial to discover safe and effective treatments to prevent male reproductive injury caused by chemotherapy. The Ganoderma lucidum polysaccharide peptide (GLPP) has multiple pharmacological activities. The purpose of this study was to determine whether GLPP could protect the male sperm production from chemotherapeutic injury using a mouse model, with testicular damage induced by cyclophosphamide (CP). CP (50 mg/kg/day) was injected intraperitoneally into male ICR mice gavaged with different doses of GLPP at certain spermatogenic stages. The experimental results showed that GLPP alleviated the CP-induced reduction in reproductive organ coefficients and sperm parameters and reduced the morphological damage of testicular tissues in a dose-dependent manner. GLPP significantly improved the reproductive index, sperm-related parameters, sex hormone levels, and histological testis architecture at different spermatogenic stages. Furthermore, GLPP significantly increased superoxide dismutase (SOD), glutathione (GSH), catalase (CAT), Nrf2, and HO-1, and decreased malondialdehyde (MDA) and Keap-1 in the testicular tissue, indicating reduced oxidative stress. In addition, GLPP limited CP-induced apoptosis via a reduction in Bax expression and increase in Bcl-2 expression. This study suggests that GLPP plays a protective role in spermatogenesis by reducing chemotherapeutic injury and might be developed into drug for male patients receiving chemotherapy.

Verified
Journal Article
Open access
PDF file
YYYuwei Ye
Yuwei Ye
AAAbudumijiti Abulizi
Abudumijiti Abulizi
YZYukun Zhang
Yukun Zhang
FLFeng Lu
Feng Lu
YAYongpan An
Yongpan An
YBYang Baoxue
Yang Baoxue
Ulcerative colitis (UC) is a chronic and recurrent gastrointestinal disease that affects millions of humans worldwide and imposes a huge social and economic burden. It is necessary to find safe and efficient drugs for preventing and treating UC. The aim of this study was to determine whether ganoderic acid (GA), the main bioactive components of Ganoderma lucidum, has preventive and therapeutic effect on UC in a dextran sulfate sodium (DSS)-induced UC mouse model. Our experimental results showed that GA significantly ameliorated the body weight loss and disease activity index (DAI) of UC mice. GA significantly restored 11% of the colon length and 69% of the spleen index compared to UC mice. GA significantly decreased the intestinal inflammatory response and improved the barrier function of the intestine by upregulating the tight junction proteins Zonula occludens-1 (ZO-1), occludin and claudin-1. A co-housing experiment showed that gut microbiota accounted for the therapeutic activity of GA on UC, which was confirmed by fecal microbiota transplantation from GA-treated mice to the UC mice. Furthermore, 16S rDNA high-throughput sequencing of fecal bacteria showed that GA significantly enriched the abundance of Lactobacillus, Oscillospira, Odoribacter and Ruminococcus, which were positively correlated with colon length. Furthermore, this study found the functional metabolites, including Indole-3-acetaldehyde (IAAld), Glutamine (Gln) and Glutathione (GSH), reduced barrier damage in the Caco-2 cell model. In conclusion, this study suggests that GA could ameliorate UC by improving intestinal barrier function via modulating gut microbiota and associated metabolites.


13 August 2025 in Journal of Advanced Research
Verified
Journal Article
Open access
FLFeng Lu
Feng Lu
CYChengfeng Yang
Chengfeng Yang
HYHao Yang
Hao Yang
PWPan Wang
Pan Wang
WZWenting Zhao
Wenting Zhao
Xiaoyan ZhaoXiaoyan Zhao
Xiaoyan Zhao
The initial 1,000 days of life represent a critical window for determining long-term health. Nutrition in early life has a significant impact on developmental programming of metabolism, immunity, and gut microbiota, with long-term implications for chronic diseases such as obesity, diabetes, and cardiovascular disease. This review compiles evidence for the role of plant-derived bioactive compounds, including polyphenols, polysaccharides, oligosaccharides, genistein, carotenoids, and chlorophyll, in early-life nutritional programming. It describes how these phytochemicals influence epigenetic control, gut microbiota colonization, and physiological development. Preclinical and clinical findings are summarized to assess their potential inclusion in infant nutrition. Early supplementation with specific phytochemicals maintains intestinal barrier function, balances gut microbiota, and supports immune and metabolic resilience. Polyphenols, oligosaccharides and polysaccharides improve beneficial microbial populations, and genistein has epigenetic regulatory activity. Carotenoids support neurodevelopment and antioxidant defense. These compounds, when administered during critical window of development, can reprogram disease susceptibility into adulthood. Although showing promise in preclinical results, human data to date are scarce, and translational issues like dosage optimization, safety, and formulation need to be resolved. The research recommends the incorporation of phytochemicals into complementary infant foods as a preventive measure against chronic diseases in adulthood, advocating for a paradigm shift towards bioactive-enhanced early-life nutrition.

12 May 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
YAYongpan An
Yongpan An
QWQian Wang
Qian Wang
PQPanshuang Qiao
Panshuang Qiao
LJLiu Jihan
Liu Jihan
AMAng Ma
Ang Ma
ZXZhengwei Xie
Zhengwei Xie
Background/Objective: Aging is a significant risk factor for chronic diseases and disability, yet effective anti-aging interventions remain elusive. We explored the potential of 3-hydroxybutyrate (3HB), an endogenous metabolite with established safety, to modulate longevity in mice. Methods: In this study, we employed 2BS and WI-38 cell models, a yeast model, and naturally aging mouse models to investigate the effects of 3HB on aging in various systems. Additionally, we utilized RNA sequencing and metabolomics technologies to explore the potential mechanisms underlying the action of 3HB. Results: Our findings demonstrate that 3HB supplementation effectively delays cellular senescence, extending yeast lifespan by 51.3% and the median lifespan of naturally senescent mice by 21.0%. Notably, 3HB prolonged healthy lifespan in mice while mitigating age-related tissue morphology changes and organ senescence. Mechanistically, we identified that 3HB’s anti-aging properties are mediated through its ability to delay cellular senescence and metabolic reprogramming, while promoting the production of beneficial metabolites like trigoneline and isoguvacine. Conclusions: These findings highlight the promising therapeutic potential of 3HB as an anti-aging intervention and provide novel insights into its underlying mechanisms.